Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

(2013) Josef S Smolen et al.   ANNALS OF THE RHEUMATIC DISEASES

Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores

(2013) Fabiola Atzeni et al.   JOINT BONE SPINE

The Effects of Tumor Necrosis Factor Inhibitors on Cardiovascular Risk in Rheumatoid Arthritis

(2012) Mike J.L. Peters et al.   CURRENT PHARMACEUTICAL DESIGN

Rheumatoid arthritis and the era of biologic therapy

(2012) Anshuman P. Malaviya et al.   INFLAMMOPHARMACOLOGY

Impact of Adherence to Antihypertensive Agents on Clinical Outcomes and Hospitalization Costs

(2010) Alice Dragomir et al.   MEDICAL CARE

Adherence, Discontinuation, and Switching of Biologic Therapies in Medicaid Enrollees with Rheumatoid Arthritis

(2010) Pengxiang Li et al.   VALUE IN HEALTH

Trends in RA patients’ adherence to subcutaneous anti-TNF therapies and costs

(2009) Bijan J. Borah et al.   CURRENT MEDICAL RESEARCH AND OPINION

Poor Adherence to Medication in Adults with Rheumatoid Arthritis

(2009) Rachel A Elliott   Disease management & health outcomes.

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis

(2008) C Potter et al.   ANNALS OF THE RHEUMATIC DISEASES

Compliance with biologic therapies for rheumatoid arthritis: Do patient out-of-pocket payments matter?

(2008) S. Curkendall et al.   ARTHRITIS AND RHEUMATISM